Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
Eur J Clin Microbiol Infect Dis. 2004 Oct; 23(10):772-5.EJ

Abstract

In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens.

Authors+Show Affiliations

Universitätsklinikum Carl Gustav Carus/Technische Universität, Fetscherstrasse 74, 01307 Dresden, Germany. gert.hoeffken@mailbox.tu-dresden.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15605184

Citation

Hoeffken, G, et al. "Efficacy and Safety of Sequential Moxifloxacin for Treatment of Community-acquired Pneumonia Associated With Atypical Pathogens." European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, vol. 23, no. 10, 2004, pp. 772-5.
Hoeffken G, Talan D, Larsen LS, et al. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis. 2004;23(10):772-5.
Hoeffken, G., Talan, D., Larsen, L. S., Peloquin, S., Choudhri, S. H., Haverstock, D., Jackson, P., & Church, D. (2004). Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 23(10), 772-5.
Hoeffken G, et al. Efficacy and Safety of Sequential Moxifloxacin for Treatment of Community-acquired Pneumonia Associated With Atypical Pathogens. Eur J Clin Microbiol Infect Dis. 2004;23(10):772-5. PubMed PMID: 15605184.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. AU - Hoeffken,G, AU - Talan,D, AU - Larsen,L S, AU - Peloquin,S, AU - Choudhri,S H, AU - Haverstock,D, AU - Jackson,P, AU - Church,D, PY - 2004/12/18/pubmed PY - 2005/1/13/medline PY - 2004/12/18/entrez SP - 772 EP - 5 JF - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology JO - Eur. J. Clin. Microbiol. Infect. Dis. VL - 23 IS - 10 N2 - In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens. SN - 0934-9723 UR - https://www.unboundmedicine.com/medline/citation/15605184/Efficacy_and_safety_of_sequential_moxifloxacin_for_treatment_of_community_acquired_pneumonia_associated_with_atypical_pathogens_ L2 - https://dx.doi.org/10.1007/s10096-004-1214-5 DB - PRIME DP - Unbound Medicine ER -